135 related articles for article (PubMed ID: 3095197)
1. [Natural inhibitors of fibrinolysis].
Juhan-Vague I; Aillaud MF; Serradimigni A
Haemostasis; 1986; 16 Suppl 4():16-20. PubMed ID: 3095197
[No Abstract] [Full Text] [Related]
2. Natural inhibitors of fibrinolysis.
Juhan-Vague I; Aillaud MF; Serradimigni A
Haemostasis; 1986; 16 Suppl 3():16-20. PubMed ID: 3095194
[No Abstract] [Full Text] [Related]
3. [Blood coagulation mechanism from the viewpoint of molecular biochemistry: Mechanism of fibrinolysis].
Matsuda T
Rinsho Byori; 1985 Sep; 33(9):982-8. PubMed ID: 2416968
[No Abstract] [Full Text] [Related]
4. [Recent progress in fibrinolytic mechanism].
Yasukouchi T
Rinsho Byori; 1986 Mar; 34(3):235-46. PubMed ID: 3086600
[No Abstract] [Full Text] [Related]
5. [Streptokinase or urokinase: the elements of choice].
Pâques EP
Haemostasis; 1986; 16 Suppl 4():21-5. PubMed ID: 2429902
[No Abstract] [Full Text] [Related]
6. [Tissue plasminogen activator: mechanism of action and thrombolytic properties].
Collen D; Lijnen HR
Haemostasis; 1986; 16 Suppl 4():26-34. PubMed ID: 3095198
[No Abstract] [Full Text] [Related]
7. [Molecular mechanisms of thrombolytic therapy].
Lijnen HR; Collen D
Haemostasis; 1986; 16 Suppl 4():3-15. PubMed ID: 2945768
[No Abstract] [Full Text] [Related]
8. [Tissue plasminogen activator: mechanism of action and thrombolytic properties].
Páramo JA; Collen D
Sangre (Barc); 1984; 29(4-C):767-73. PubMed ID: 6393389
[No Abstract] [Full Text] [Related]
9. Plasminogen activator inhibitor type 1: biochemistry and evidence for modulation of fibrinolysis in vivo.
Krishnamurti C; Alving BM
Semin Thromb Hemost; 1992 Jan; 18(1):67-80. PubMed ID: 1374195
[No Abstract] [Full Text] [Related]
10. An assessment of regional versus systemic thrombolytic treatment of peripheral and coronary artery thrombosis.
Marder VJ; Francis CW
Prog Hemost Thromb; 1984; 7():325-56. PubMed ID: 6241729
[No Abstract] [Full Text] [Related]
11. Acceleration of plasma clot lysis by an antibody to alpha 2-antiplasmin.
Reed GL; Matsueda GR; Haber E
Trans Assoc Am Physicians; 1988; 101():250-6. PubMed ID: 2480017
[No Abstract] [Full Text] [Related]
12. Plasminogen activator inhibitor: a regulator of ancrod-induced fibrin deposition in rabbits.
Krishnamurti C; Barr CF; Hassett MA; Young GD; Alving BM
Blood; 1987 Mar; 69(3):798-803. PubMed ID: 3101764
[TBL] [Abstract][Full Text] [Related]
13. [Inhibition by ethanol and acetaldehyde the plasmin activity and plasminogen activation induced by urokinase and streptokinase].
Roszkowska-Jakimiec W; Jurkowski J; Ostrowska H; Worowski K
Rocz Akad Med Bialymst (1989); 1988-1989; 33-34():53-66. PubMed ID: 2979011
[TBL] [Abstract][Full Text] [Related]
14. Importance of fibrin specificity in therapeutic thrombolysis and the rationale of using sequential and synergistic combinations of tissue plasminogen activator and pro-urokinase.
Gurewich V
Semin Thromb Hemost; 1989 Apr; 15(2):123-8. PubMed ID: 2501871
[No Abstract] [Full Text] [Related]
15. [Structure, function and use of fibrinolysis-promoting and inhibiting factors].
Bachmann F
Arzneimittelforschung; 1988 Mar; 38(3A):474-8. PubMed ID: 3134901
[TBL] [Abstract][Full Text] [Related]
16. Concepts of clot lysis.
Francis CW; Marder VJ
Annu Rev Med; 1986; 37():187-204. PubMed ID: 2939790
[TBL] [Abstract][Full Text] [Related]
17. The antifibrinolytic effects of carbon monoxide-releasing molecule-2 are fibrin and alpha2-antiplasmin dependent.
Nielsen VG
Blood Coagul Fibrinolysis; 2010 Sep; 21(6):584-7. PubMed ID: 20683324
[TBL] [Abstract][Full Text] [Related]
18. [Current developments in fibrinolytic therapy].
Rijken DC
Ned Tijdschr Geneeskd; 1985 Sep; 129(37):1768-72. PubMed ID: 3934567
[No Abstract] [Full Text] [Related]
19. [Molecular mechanisms of fibrinolysis and perspectives of thrombolytic therapy].
Veremeenko KN; Kizim AI
Vopr Med Khim; 1984; 30(5):13-22. PubMed ID: 6084892
[TBL] [Abstract][Full Text] [Related]
20. Fibrinolysis--a review.
Kane KK
Ann Clin Lab Sci; 1984; 14(6):443-9. PubMed ID: 6239587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
